Literature DB >> 33350849

Trim47 overexpression correlates with poor prognosis in gastric cancer.

YuJian Xia1, ZheWei Wei1, WeiBin Huang1, XiaoJing Wei2, YuLong He1.   

Abstract

Trim47 is a member of the tripartite motif (TRIM) family that participates in many pathophysiological processes. However, the expression pattern and biological functions of Trim47 in gastric cancer (GC) remain unclear. The present study aimed to further explore the clinicopathological significance and potential prognostic role of Trim47 expression in GC. Therefore, in this study, Trim47 mRNA level was investigated in the Cancer Genome Atlas (TCGA) and Oncomine database in GC. We detected Trim47 mRNA and protein expression levels in GC and paired adjacent normal tissues. Kaplan-Meier method and Cox proportional hazard regression models were performed to analyze the survival of patients and prognostic factors. A gene set enrichment analysis (GSEA) was performed to determine the mechanism of Trim47 in GC. Our results indicated that Trim47 mRNA expression in GC tissues was significantly higher than adjacent normal tissues, as was Trim47 protein expression. Trim47 overexpression in GC tissues was significantly associated with tumor differentiation, T stage, N stage, M stage, and TNM stage. Kaplan-Meier analyses showed that high Trim47 expression was associated with worse overall survival (OS) and disease-free survival (DFS) in GC patients. Multivariate analysis confirmed that Trim47 expression was an independent prognostic factor for GC patients. Bioinformatics analysis and western blot indicated Trim47 might regulate GC through NF-κB, EMT, hypoxia, and apoptosis signaling pathway in GC. Our results show that Trim47 has the potential to serve as a novel prognostic biomarker in GC patients.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33350849     DOI: 10.4149/neo_2020_200708N706

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  4 in total

Review 1.  TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Authors:  Ning Huang; Xiaolin Sun; Peng Li; Xin Liu; Xuemei Zhang; Qian Chen; Hong Xin
Journal:  Exp Hematol Oncol       Date:  2022-10-19

2.  NAT10 promotes gastric cancer metastasis via N4-acetylated COL5A1.

Authors:  Yigan Zhang; Yuanxue Jing; Yinxue Wang; Jianming Tang; Xiaoran Zhu; Wei-Lin Jin; Yiqing Wang; Wenzhen Yuan; Xiangkai Li; Xun Li
Journal:  Signal Transduct Target Ther       Date:  2021-05-03

3.  Comprehensive Analysis of the Prognostic Values of the TRIM Family in Hepatocellular Carcinoma.

Authors:  Weiyu Dai; Jing Wang; Zhi Wang; Yizhi Xiao; Jiaying Li; Linjie Hong; Miaomiao Pei; Jieming Zhang; Ping Yang; Xiaosheng Wu; Weimei Tang; Xiaoling Jiang; Ping Jiang; Li Xiang; Aimin Li; Jianjiao Lin; Side Liu; Jide Wang
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

4.  ERCC6L promotes cell growth and metastasis in gastric cancer through activating NF-κB signaling.

Authors:  Dehu Chen; Qinghong Liu; Gan Cao
Journal:  Aging (Albany NY)       Date:  2021-08-23       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.